相关实验视频

Updated: May 9, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

通过BET-PROTAC向Myc,在扩散大B细胞淋巴瘤中产生强大的抗淋巴瘤活性

Hui Wang^1,2, Ximei Wu^1,2, Jingjing Gao^1,2

¹Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, China.

Investigational new drugs

|April 30, 2025

概括

与传统的抑制剂相比,BET蛋白质分解向嵌合体 (PROTACs) 对扩散型大B细胞淋巴瘤 (DLBCL) 显示出优异的抗瘤活性. 一种BET PROTAC的ARV-825有效降解c-Myc和BET蛋白,为DLBCL治疗提供了一个有前途的新策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 的预后不佳,c-Myc被确定为关键的治疗点.
直接准c-Myc是具有挑战性的;然而,原蛋白和外地蛋白 (BET) 蛋白家族调节c-Myc,并提供了另一种治疗途径.
针对BET蛋白质分解的仿真体 (PROTACs) 为降解BET蛋白提供了一种新的方法,可能比BET抑制剂提供更持久的效果.

研究的目的:

在DLBCL中比较BET PROTAC (ARV-825) 与BET抑制剂 (JQ1) 的抗瘤疗效.
评估ARV-825和JQ1对DLBCL细胞增殖,细胞亡,细胞循环和c-Myc/BET蛋白水平的影响.
在DLBCL小鼠模型中评估ARV-825的体内疗效.

主要方法:

细胞增殖试验 (CCK-8),细胞亡分析 (Annexin V/PI染色) 和细胞周期分析 (PI染色).
西部涂抹测定BET家族蛋白质和c-Myc表达水平.
使用SCID小鼠模型植入SU-DHL-4细胞的体内疗效研究.

主要成果:

与JQ1.1.相比,ARV-825表现出优异的DLBCL细胞增殖抑制,增强的亡诱导,并促进细胞循环停止.
在降低BET蛋白和c-Myc水平方面,ARV-825比JQ1更有效,在体外和体内.
在体内小鼠模型中,ARV-825治疗导致延长生存时间.

结论:

以ARV-825为例的BET PROTACs对DLBCL具有显著的抗瘤活性.
ARV-825有效降解BET蛋白和c-Myc的能力表明它有可能成为DLBCL的新治疗策略.
这些发现支持对BET PROTACs用于治疗扩散性大B细胞淋巴瘤的临床研究.

关键词:

BET BET 在线投注这就是C-Mycc.扩散性大B细胞淋巴瘤抑制剂的抑制剂这就是PROTAC.蛋白质降解蛋白质降解

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...